Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort

Clinical Infectious Diseases

Volumn 56, Issue 9, 2013, Pages 1248-1254

  Witt, Maxwell A ^a   Arias, Larry ^a   Katz, Paul H ^a   Truong, Elizabeth T ^a   Witt, David J ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

acellular pertussis vaccine; Bordetella pertussis; pertussis vaccine; whole cell pertussis vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; WHOLE CELL PERTUSSIS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; RISK REDUCTION; SCHOOL CHILD; UNITED STATES; VACCINATION;

ADOLESCENT; CHILD; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; PERTUSSIS VACCINE; PREVALENCE; RISK FACTORS; UNITED STATES; VACCINES, ACELLULAR; WHOOPING COUGH; YOUNG ADULT;

EID: 84876000191     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit046     Document Type: Article

References (23)

1. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in pre-adolescents in a North American outbreak. Clin Infect Dis 2012; 54:1730-5.
2. Rendi-Wagner P, Kundi M, Mikolasek A, Vecsei A, Fruhwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine 2006; 24:5960-5. (Pubitemid 44080365)
3. Lacombe K, Yam A, Simondon K, Pinchinat S, Simondon F. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine 2004; 23:623-8. (Pubitemid 39473191)
4. Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010; 51:315-21.
5. Weekly pertussis update for Washington State. Available at: http://www.doh.wa.gov/Portals/1/Documents/Pubs/348-254-PertussisUpdate. pdf. Accessed 25 June 2012.
6. Table: whooping cough ( pertussis) laboratory reports in England and Wales by region and age group, 2008-2011 (confirmed by culture, PCR and/or serology). Available at: http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/ HPAweb-C/1317132184294. Accessed 4 July 2012.
7. Mettner J. The COUGH that won't quit: why pertussis has made a comeback. Minn Med 2012; 95:18-22.
8. Pertussis report, Wisconsin. Available at: http://www.dhs.wisconsin. gov/immunization/pdf/pertreport.pdf. Accessed 20 June 2012.
9. Cherry JD. Why do pertussis vaccines fail? Pediatrics 2012; 129:968-70.
10. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 2011; 1:CD001478.
11. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555-63. (Pubitemid 41434634)
12. Witt MA, Katz PH, Witt DJ. Reply to Guiso, Misegades et al, and Sheridan and Lambert. Clin Infect Dis 2012; 55:1435-6.
13. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454-6.
14. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115:1422-7. (Pubitemid 43852794)
15. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-13):1-8.
16. Chen RT, Orenstein WA. Epidemiologic methods in immunization programs. Epidemiol Rev 1996; 18:99-117. (Pubitemid 27082083)
17. Salmaso S, Mastrantonio P, Tozzi AE, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001; 108:E81.
18. Lind-Brandberg L, Welinder-Olsson C, Lagergard T, Taranger J, Trollfors B, Zackrisson G. Evaluation of PCR for diagnosis of Bordetella pertussis and Bordetella parapertussis infections. J Clin Microbiol 1998; 36:679-83. (Pubitemid 28093249)
19. Templeton KE, Scheltinga SA, van der Zee A, et al. Evaluation of realtime PCR for detection of and discrimination between Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii for clinical diagnosis. J Clin Microbiol 2003; 41:4121-6. (Pubitemid 37099674)
20. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326-82. (Pubitemid 40548297)
21. Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children. recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 1997; 46(RR-7):1-25.
22. Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, et al. California pertussis epidemic, 2010. J Pediatr 2012; 161:1091-6.
23. Farizo KM, Cochi SL, Zell ER, Brink EW, Wassilak SG, Patriarca PA. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992; 14:708-19.